What is the recommended management of retinal vein occlusion?

Management of Retinal Vein Occlusion

Anti-VEGF agents are the preferred first-line therapy for macular edema associated with both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), with intravitreal corticosteroids or laser reserved for inadequate responders. 1

Initial Treatment Approach

For Macular Edema (Primary Complication)

Start with anti-VEGF therapy immediately when macular edema is present, as early treatment yields superior visual outcomes compared to delayed intervention 1. The evidence strongly supports anti-VEGF agents over other modalities due to their favorable risk-benefit profile and minimal systemic thromboembolic risk 1.

Anti-VEGF Agent Selection

Three agents are available with comparable efficacy:

• Aflibercept (FDA-approved): Demonstrated 15-letter gain in 56% of CRVO patients vs 12% with sham 1
• Ranibizumab (FDA-approved): Showed 16-18 letter gain in BRVO, with 55-61% gaining ≥15 letters vs 29% with sham 1, 2
• Bevacizumab (off-label): SCORE2 trial showed similar efficacy to aflibercept at 6 months for CRVO 1

The SCORE2 data indicates aflibercept and bevacizumab perform similarly, though confidence intervals suggest caution in declaring complete equivalence 1. Choose based on availability, cost considerations, and institutional protocols.

Treatment Regimen

• Initial phase: Monthly injections for the first 6 months
• Maintenance phase: Consider treat-and-extend protocol after good response, which reduces injection burden by 1-2 injections compared to monthly dosing while maintaining visual outcomes 1
• Critical caveat: Delaying treatment beyond 6 months significantly compromises final visual outcomes—eyes starting anti-VEGF after initial observation never catch up to those treated immediately 1

Injection Technique Standards

• Use topical povidone-iodine before all intravitreal injections 1
• Do NOT use routine prophylactic antibiotic drops—they are not recommended 1, 2
• Severe complications (endophthalmitis, retinal detachment, cataract) are uncommon 1

Second-Line and Rescue Therapies

When to Switch from Anti-VEGF

Consider alternative therapy when:

• Poor response after 6 months of monthly anti-VEGF treatment
• Marginal response requiring rescue therapy
• Persistent macular edema despite adequate anti-VEGF dosing

Intravitreal Corticosteroids

Use as second-line or in specific circumstances:

• Dexamethasone implant (Ozurdex): FDA-approved for both BRVO and CRVO; provides visual gains at 90 days but effect diminishes by 6 months, requiring repeat dosing 2
• Triamcinolone: SCORE trial showed 1 mg dose preferred over 4 mg due to lower rates of cataract and IOP elevation while maintaining similar efficacy (approximately one-third gained ≥15 letters) 1, 2

Major risks: Cataract formation and elevated IOP are significantly more common than with anti-VEGF agents 1, 2. This makes corticosteroids less favorable as first-line therapy despite proven efficacy.

Consider corticosteroids primarily in:

• Patients with high systemic cardiovascular risk where anti-VEGF may be relatively contraindicated 3
• Poor responders to anti-VEGF at 6 months (dexamethasone rescue) 1

Laser Photocoagulation

Grid laser for BRVO only:

• SCORE trial showed grid laser had similar efficacy to corticosteroids for BRVO (mean 4-5 letter gain) 1
• Consider when anti-VEGF or corticosteroids fail or are contraindicated 1
• No role in CRVO—laser does not benefit central occlusions 4
• May serve as adjunctive therapy in BRVO, though combination with anti-VEGF shows no additional benefit over monotherapy 5

Systemic Risk Factor Management

Coordinate with primary care immediately to address underlying vascular disease 2:

Essential Systemic Workup

• Hypertension: Present in 48% of RVO cases—the strongest modifiable risk factor 1
• Hyperlipidemia: Accounts for 20% of RVO cases 1
• Diabetes: Contributes to 5% of cases 1
• Glaucoma/ocular hypertension: Particularly associated with CRVO 2

Critical Communication Point

Patients with RVO have:

• Higher risk of fellow eye involvement
• Increased cardiovascular disease risk
• Elevated cerebrovascular accident risk 1

Document end-organ damage and communicate findings to the primary care provider for comprehensive cardiovascular risk reduction 2.

Monitoring and Prognosis

Follow-up Schedule

• During active treatment: Monthly for injection assessment
• After stabilization: Quarterly monitoring acceptable with treat-and-extend protocols 1
• Long-term: RVO is a chronic disease requiring individualized long-term monitoring 3

Neovascularization Surveillance

• CRVO/hemi-CRVO: Higher risk of anterior segment neovascularization and neovascular glaucoma—requires vigilant monitoring 2
• BRVO/HRVO: More likely to develop retinal neovascularization 2
• Consider panretinal photocoagulation if neovascularization develops and reliable monitoring is not feasible 3

Common Pitfalls to Avoid

1. Delaying treatment: Waiting beyond initial presentation significantly compromises final visual outcomes 1
2. Using routine antibiotic drops: Not recommended and adds unnecessary cost/exposure 1, 2
3. Choosing corticosteroids first-line: Higher complication rates (cataract, glaucoma) make them less favorable despite efficacy 1, 2
4. Applying BRVO laser protocols to CRVO: Grid laser has no role in CRVO management 4
5. Inadequate systemic evaluation: Missing the opportunity to reduce cardiovascular morbidity and fellow eye risk 1, 2